Nuttada Panpradist

Dr. Nuttada Panpradist

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Science Translational Medicine
Verified
Journal Article
Open access
AHAndrew C. Hunt
Andrew C. Hunt
JCJames Brett Case
James Brett Case
YPYoung-Jun Park
Young-Jun Park
LCLongxing Cao
Longxing Cao
KWKejia Wu
Kejia Wu
DBDavid Baker
David Baker
New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2. We found the broadest efficacy was achieved with a homotrimeric version of the 75-residue angiotensin-converting enzyme 2 (ACE2) mimic AHB2 (TRI2-2) designed to geometrically match the trimeric spike architecture. Consistent with the design model, in the cryo-electron microscopy structure TRI2-2 forms a tripod at the apex of the spike protein that engaged all three receptor binding domains simultaneously. TRI2-2 neutralized Omicron (B.1.1.529), Delta (B.1.617.2), and all other variants tested with greater potency than the monoclonal antibodies used clinically for the treatment of COVID-19. TRI2-2 also conferred prophylactic and therapeutic protection against SARS-CoV-2 challenge when administered intranasally in mice. Designed miniprotein receptor mimics geometrically arrayed to match pathogen receptor binding sites could be a widely applicable antiviral therapeutic strategy with advantages over antibodies in greater resistance to viral escape and antigenic drift, and advantages over native receptor traps in lower chances of autoimmune responses.

9 May 2022 in Analytical Chemistry
Verified
Journal Article
Closed access
LYLucy F. Yang
Lucy F. Yang
NKNataly Kacherovsky
Nataly Kacherovsky
NPNuttada Panpradist
Nuttada Panpradist
RWRuixuan Wan
Ruixuan Wan
JLJoey Liang
Joey Liang
SPSuzie H. Pun
Suzie H. Pun

17 December 2021 in Science Advances
Verified
Journal Article
Open access
NPNuttada Panpradist
Nuttada Panpradist
EKEnos C. Kline
Enos C. Kline
RARobert G. Atkinson
Robert G. Atkinson
MRMichael Roller
Michael Roller
QWQin Wang
Qin Wang
BLBarry Lutz
Barry Lutz
A unique four-plexed RT-LAMP test kit operated by health workers can provide faster, more sensitive results than laboratory tests.

26 January 2024 in JHEP Reports
Verified
Journal Article
Open access
PDPojsakorn Danpanichkul
Pojsakorn Danpanichkul
KSKanokphong Suparan
Kanokphong Suparan
CNCheng Han Ng
Cheng Han Ng
DDDisatorn Dejvajara
Disatorn Dejvajara
SKSiwanart Kongarin
Siwanart Kongarin
KWKarn Wijarnpreecha
Karn Wijarnpreecha
Alcohol-associated liver diseases (ALDs) and alcohol use disorder (AUD) pose a global health risk. AUD is underrecognized in the elderly, and the burden of AUD complications, including ALD, may increase with aging populations and rising alcohol intake. However, there is a lack of epidemiological evidence on AUD and ALD in the elderly. Using the Global Burden of Disease Study 2019, we analyzed the prevalence, mortality, disability-adjusted life years (DALYs), age-standardized rates (ASRs), and temporal change from 2000 to 2019 of ALD and AUD in the overall population and the elderly (65–89 years). The findings were categorized by sex, region, nation, and sociodemographic index. The prevalence rates of ALD in the elderly were higher than those in adolescents and young adults, whereas AUD levels were lower than those in adolescents and young adults. In 2019, there were 9.39 million cases (8.69% of cases in the overall population) of AUD, 3.23 million cases (21.8% of cases in the overall population) of alcohol-associated cirrhosis, and 68,468 cases (51.27% of cases in the overall population) of liver cancer from alcohol among the elderly. ASRs of the prevalence of ALD and AUD in the elderly increased in most regions; on the contrary, ASRs of death and DALYs decreased in most regions. Nevertheless, ASRs of death and DALYs from liver cancer from alcohol increased in many areas. Our findings highlighted the increased prevalence of ALD in the elderly, with a burden of AUD comparable with that in the overall population. Public health strategies on ALD and AUD targeting the elderly are urgently needed. The burden of alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) is increasing. Advances in healthcare and education have resulted in a remarkable spike in life expectancy and a consequential population aging. Nevertheless, little is known about the epidemiology of ALD and AUD in the elderly. Our study indicates the increasing burden of ALD and AUD in the elderly population, necessitating early detection, intervention, and tailored care to the unique needs and complexities faced by older individuals grappling with these conditions.

1 February 2021 in EBioMedicine
Verified
Journal Article
Open access
NPNuttada Panpradist
Nuttada Panpradist
QWQin Wang
Qin Wang
PRParker S. Ruth
Parker S. Ruth
JKJack H. Kotnik
Jack H. Kotnik
AOAmy K. Oreskovic
Amy K. Oreskovic
BLBarry Lutz
Barry Lutz
Detection of SARS-CoV-2 infections is important for treatment, isolation of infected and exposed individuals, and contact tracing. RT-qPCR is the "gold-standard" method to sensitively detect SARS-CoV-2 RNA, but most laboratory-developed RT-qPCR assays involve complex steps. Here, we aimed to simplify RT-qPCR assays by streamlining reaction setup, eliminating RNA extraction, and proposing reduced-cost detection workflows that avoid the need for expensive qPCR instruments. A low-cost RT-PCR based "kit" was developed for faster turnaround than the CDC developed protocol. We demonstrated three detection workflows: two that can be deployed in laboratories conducting assays of variable complexity, and one that could be simple enough for point-of-care. Analytical sensitivity was assessed using SARS-CoV-2 RNA spiked in simulated nasal matrix. Clinical performance was evaluated using contrived human nasal matrix (n = 41) and clinical nasal specimens collected from individuals with respiratory symptoms (n = 110). The analytical sensitivity of the lyophilised RT-PCR was 10 copies/reaction using purified SARS-CoV-2 RNA, and 20 copies/reaction when using direct lysate in simulated nasal matrix. Evaluation of assay performance on contrived human matrix showed 96.7-100% specificity and 100% sensitivity at ≥20 RNA copies. A head-to-head comparison with the standard CDC protocol on clinical specimens showed 83.8-94.6% sensitivity and 96.8-100% specificity. We found 3.6% indeterminate samples (undetected human control), lower than 8.1% with the standard protocol. This preliminary work should support laboratories or commercial entities to develop and expand access to Covid-19 testing. Software guidance development for this assay is ongoing to enable implementation in other settings. FUND: USA NIH R01AI140845 and Seattle Children's Research Institute.

26 December 2023 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDPojsakorn Danpanichkul
Pojsakorn Danpanichkul
CNCheng Han Ng
Cheng Han Ng
MMMark Muthiah
Mark Muthiah
KSKanokphong Suparan
Kanokphong Suparan
DTDarren Jun Hao Tan
Darren Jun Hao Tan
KWKarn Wijarnpreecha
Karn Wijarnpreecha
INTRODUCTION: The burden of alcohol-related complications is considerable, particularly alcohol-associated liver disease and alcohol use disorder (AUD). However, there are deficiencies in comprehensive epidemiological research focusing on these issues, especially among young women who display higher susceptibility to such complications compared with their male counterparts. We thus aimed to determine the global burden of these conditions in this vulnerable group. METHODS: Leveraging data from the Global Burden of Disease Study 2019, we analyzed the prevalence, mortality, and disability-adjusted life years of alcohol-associated cirrhosis (AC), liver cancer from alcohol, and AUD in young women. The findings were categorized by region, nation, and sociodemographic index. RESULTS: The highest age-standardized prevalence rates were observed in AUD (895.96 [95% uncertainty interval (UI) 722.6–1,103.58]), followed by AC (65.33 [95% UI 48.37–86.49]) and liver cancer from alcohol (0.13 [95% UI 0.09–0.19]) per 100,000 people. The highest age-standardized mortality rates were observed in AC (0.75 [95% UI 0.55–0.97]), followed by AUD (0.48 [95% UI 0.43–0.53]) and liver cancer from alcohol (0.06 [95% UI 0.04–0.09]). The highest burdens of AC and AUD were observed in Central Europe, whereas the high-income Asia Pacific had the highest burden of liver cancer from alcohol. DISCUSSION: Throughout the past decade, the trend of AUD varied among regions while the impact of alcohol-associated liver disease has increased, requiring urgent public health strategy to mitigate these complications, particularly in female patients in Europe and the Asia-Pacific region.